Supernus Pharma (SUPN) Tops Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Supernus Pharma (SUPN) Tops Q4 EPS by 3c

Supernus Pharmaceuticals (SUPN) PT Raised to $16 at Piper Jaffray Post Q4

March 12, 2015 7:21 AM EDT

Piper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $16.00 (from $14.00) following Q4 results, noting continued strength for the epilepsy franchise.

Amsellem commented, "Supernus reported non-GAAP EPS of $0.08 on revenues of $31M, well... More